Skip to main content
. 2017 Oct 5;31(16):2295–2301. doi: 10.1097/QAD.0000000000001639

Table 1.

Characteristics of the study population of the anal intraepithelial neoplasia cohort study by histological high-grade squamous intraepithelial lesion status, Amsterdam 2008–2015 (N = 1678).

Total (N = 1678) No dysplasia (N = 785) LSIL (N = 396) HSIL (N = 497)
No. % No % No. % No. % P value
Demographic variables
 Age in years (mean/SD)a 49 (9.6) 50 (9.4) 48 (10.0) 48 (9.3) <0.001
 Continent of birthb 0.710
  Europe 1279 82% 566 82% 305 81% 408 84%
  Americas 188 12% 83 12% 50 13% 55 11%
  Oceania 11 1% 5 1% 1 0% 5 1%
  Asia 46 3% 22 3% 14 4% 10 2%
  Africa 28 2% 13 2% 8 2% 7 1%
 Smoking statusc 0.481
  Never smoked 598 38% 275 38% 145 39% 178 39%
  Previously smoking 379 24% 191 26% 83 22% 105 23%
  Currently smoking 577 37% 256 35% 145 39% 176 38%
 Number of sex partners in the preceding 6 months (median/IQR)d 2 (1–6) 1 (1–5) 2 (1–6) 2 (1–7) 0.016
 Number of sex partners in the preceding 6 monthsd 0.166
  0–1 598 49% 295 52% 141 48% 162 44%
  2–5 304 25% 131 23% 77 26% 96 26%
  ≥6 316 26% 136 24% 73 25% 107 29%
 Had an STD in the preceding 6 months 0.066
  No 1586 95% 750 96% 376 95% 460 93%
  Yes 92 5% 35 4% 20 5% 37 7%
HIV-related variables
 Currently using cARTe 0.124
  No 73 4% 26 3% 23 6% 24 5%
  Yes 1580 96% 743 97% 368 94% 469 95%
 Duration of cART use in years (median/IQR)f 7.8 (4.0–12.4) 8.9 (4.8–12.8) 6.6 (3.6–11.8) 7.5 (3.1–12.3) <0.001
 CD4+ T-cell count cells/μl (median/IQR)g 620 (480–790) 620 (480–800) 605 (450–780) 630 (490–800) 0.236
 CD4+ T-cell count cells/μl g 0.423
  <350 168 10% 75 10% 48 12% 45 9%
  350–500 323 20% 153 20% 81 21% 89 18%
  >500 1163 70% 541 70% 265 67% 357 73%
 Nadir CD4+ T-cell count cells/μl (median/IQR)h 220 (130–320) 220 (130–310) 220 (120–320) 222 (130–351) 0.357
 Nadir CD4+ T-cell count cells/μlh 0.005
  <100 315 19% 146 19% 79 20% 90 18%
  100–199 368 22% 168 22% 86 22% 114 23%
  200–349 624 38% 315 41% 153 39% 156 32%
  >350 344 21% 138 18% 76 19% 130 26%
 HIV plasma viral load copies/ml (median/IQR)i 20 (1–40) 20 (1–40) 20 (1–40) 20 (1–40) 0.211
 HIV viral load copies/mli 0.001
  <50 1347 89% 620 92% 315 85% 412 88%
  ≥50 161 11% 51 8% 56 15% 54 12%
 Years living with viral suppression (median/IQR)j,k 6.3 (2.6–11.1) 7.2 (3.7–11.8) 5.1 (2.0–10.1) 5.9 (1.9–11.0) <0.001
 Years living with viral suppressionj,k <0.001
  <1 yearl 203 14% 61 9% 57 16% 85 18%
  1–5 years 411 28% 172 26% 117 33% 122 26%
  5.01–10 years 393 27% 187 28% 94 26% 112 24%
  >10 years 476 32% 238 36% 92 26% 146 31%
 Having had an AIDS defining illnessm,n 0.803
  No 1280 78% 575 78% 313 79% 392 79%
  Yes 354 22% 166 22% 83 21% 105 21%
Clinic
 Clinic where HRA was done 0.008
  Clinic A 710 42% 334 43% 163 41% 213 43%
  Clinic B 674 40% 288 37% 176 44% 210 42%
  Clinic C 294 17% 163 21% 57 14% 74 15%
AIN diagnosis
 No dysplasia 785 47%
 AIN1 396 24%
 AIN2 289 17%
 AIN3 208 12%
Location HSIL
 Intra-anal HSIL 474 28%
 Perianal HSIL 46 3%

AIN, anal intraepithelial neoplasia; cART, combination antiretroviral therapy; HSIL, high-grade squamous intraepithelial lesion; IQR, interquartile range; LSIL, low-grade squamous intraepithelial lesion; STD, sexually transmitted disease.

aTotal – 1 missing; no dysplasia – 1 missing; LSIL – 0 missings; HSIL – 0 missings.

bTotal – 126 missings; no dysplasia – 96 missings; LSIL – 18 missings; HSIL – 12 missings.

cTotal – 124 missings; no dysplasia – 63 missings; LSIL – 23 missings; HSIL – 38 missings.

dTotal – 460 missings; no dysplasia – 223 missings; LSIL – 105 missings; HSIL – 132 missings.

eTotal – 25 missings; no dysplasia – 16 missings; LSIL – 5 missings; HSIL – 4 missings.

fTotal – 93 missings; no dysplasia – 39 missings; LSIL – 27 missings; HSIL – 27 missings.

gTotal – 24 missings; no dysplasia – 16 missings; LSIL – 2 missings; HSIL – 6 missings.

hTotal – 27 misisngs; no dysplasia – 18 missings; LSIL – 2 missings; HSIL – 7 missings.

iTotal – 170 missings; no dysplasia – 113 missings; LSIL – 26 missings; HSIL – 31 missings.

jTotal – 196 missings; no dysplasia – 127 missings; LSIL – 36 missings; HSIL – 33 missings.

kViral suppression was defined as having a viral load of less than 200 in tests from 1 August 1999 onwards allowing for a onetime blip in viral load between 200 and 400 copies/ml. For samples tested prior to 1 August 1999 the cut-off of detectability of the laboratory assay that was used for that sample is the cut-off for viral suppression.

lParticipants who never had an undetectable viral load are included in the category less than 1-year undetectable viral load.

mTotal – 45 missings; no dysplasia – 44 missings; LSIL – 0 missing; HSIL – 1 missing.

nIncluded AIDS defining illnesses: candidiasis esophageal, Kaposi's sarcoma, recurrent pneumonia, chronic intestinal microsporidiosis, pneumocystis carinii pneumonia, Mycobacterium kansasii, pulmonary tuberculosis, chronic intestinal cryptosporidiosis, AIDS dementia complex/HIV encephalopathy, toxoplasmosis of the brain, other species/unidentified extrapulmonary mycobacterium, cytomegalovirus (CMV) retinitis, non-Hodgkin's lymphoma, CMV disease (other than lymph node, liver, spleen), herpes simplex virus, progressive multifocal leucoencephalopathy, extrapulmonary cryptococcosis, primary lymphoma of central nervous system, extrapulmonary tuberculosis, wasting syndrome because of HIV, disseminated or extrapulmonary histoplasmosis, visceral leishmaniasis, candidiasis of trachea/bronchi/lungs, disseminated or extrapulmonary coccidioidomycosis, extrapulmonary pneumocystis, other CDC C event.